The Board of Directors of the Company have approved the Audited Financial Results for the Quarter and Year ended March 31st 2025 at their meeting held on May 9, 2025.

Revenue growth above 20%Net loss reportedNegative operating cash flowResults View source PDF Explain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-5.5%Reaction day

₹28.57

prior close

₹27.97

announcement price

In-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-0.1%-5.4% vs market

Pharmaceuticals peers, median of 146sector-0.2%-5.3% vs sector

On the reaction day the stock moved 5.4 pts less than Nifty Microcap 250 and 5.3 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.0

10m

+0.0

15m

+0.0

30m

-0.3

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-5.5-0.1-5.4-0.2-5.3

Next day

-1.6+4.5-6.2+2.5-4.1

-5.6+6.2-11.8+4.0-9.5

-10.2+7.9-18.1+4.4-14.6

-5.7+9.0-14.7+5.1-10.8

-2.1+9.9-11.9+5.5-7.5

-6.9+10.0-16.9+5.5-12.4

15d

-12.1+13.1-25.2+7.3-19.5

-15.2+15.5-30.7+7.9-23.0

-19.7+16.8-36.5+8.9-28.6

+2.3+11.3-9.0+3.1-0.7

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 146Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

The board approved audited standalone financial results for FY25 at its May 9, 2025 meeting. Total revenue jumped sharply to Rs. 186.05 lakhs in FY25 from Rs. 19.86 lakhs in FY24, driven by revenue from operations of Rs. 80.73 lakhs (against nil earlier) and other income of Rs. 105.32 lakhs. However, the company slipped into a loss with FY25 profit after tax at Rs. (1.05) lakhs versus a profit of Rs. 6.45 lakhs last year, and EPS turned negative at Rs. (0.02). The company also raised Rs. 507.26 lakhs via 1,00,25,000 convertible warrants allotted on a preferential basis, boosting cash from operations-related outflows significantly. The statutory auditor PPKG & Co. issued an unmodified (clean) opinion on the results.

Likely market impact

The sharp revenue jump is encouraging but the bottom-line loss and negative operating cash flow of Rs. 229 lakhs suggest the business is still not self-sustaining. The fresh warrant infusion improves liquidity for now, but shareholders should watch whether the company can convert this into genuine operational profits in coming quarters.